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Background: Activation of the renin system plays an important role in the complications of diabetes mellitus. In this study, we assessed the 
contribution of obesity and abnormal glycemic control to altered renal hemodynamics.
Methods: We consecutively enrolled subjects with type 2 diabetes mellitus and subjects with normal glycemic control. Renal plasma flow was 
measured by para-aminohippurate (PAH) clearance in subjects on high salt diet. To assess renin system activity we measured the acute renovascular 
response to angiotensin converting enzyme (ACE) inhibition with captopril (25 mg dose). PAH clearance was measured at baseline and following the 
administration of captopril and the peak response was recorded. All values were normalized to body surface area and the percentage increase in 
PAH clearance was calculated.
Results: We studied 18 subjects (11 [61%] males) with diabetes mellitus and 32 healthy subjects15 [47%] males) with normal glycemic control. 
Patients with diabetes were older (56.7 ±9.6 vs. 42.0 ± 16.8 years; p=0.004) and had a higher body mass index (BMI) (32.4 ± 5.7 vs. 27.7 ± 
4.4 kg/m2; p = 0.002). Baseline PAH clearance was lower in patients with diabetes than in controls (407 ± 61 vs. 522 ± 79 ml/min/1.7 m2; 
p <0.0001). Diabetics had a significantly higher percentage increase in PAH clearance post captopril (9.6 ± 10.2 vs. 2.7 ± 9.8%; p = 0.02). In 
addition, overweight/obese patients (BMI ≥25) had a significantly higher response than those with a BMI of <25 (7.0 ± 10.0 vs. -3.1 ± -12.1%; 
p=0.006). In a multivariable regression model including all patients, younger age (p<001), diabetes (p=0.02) and overweight/diabetes status 
(p=0.01) were associated with an enhanced response to captopril.
Conclusions: In diabetics, the renal vasodilator response to captopril in a high salt state is enhanced, probably reflecting heightened renin-
angiotensin-system activation in these patients. Increased BMI was associated with enhanced response to ACE inhibition, reflecting a contribution of 
overweight/obesity status to the renal hemodynamics, and potentially to the increased risk of diabetic nephropathy.
